Video: Ekso Bionics Killed by Naked Short Sellers – Is HCWainwright Culpable for Front-Running Their Death?
How it works:
Article: Has Wall Street Stolen $100 Trillion from the American Public? Will Donald Trump Get It Back?
Has Wall Street Stolen $100 Trillion from the American Public? Will Donald Trump Get It Back? Tehran Times, May 26, 2020 – International TEHRAN – Robert David Steele, a former Marine Corps infantry officer and CIA spy as well as an activist for Open Source Everything Engineering (OSEE), contributes regularly to Tehran Times.
Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright Austin Angelo AnalystRatings, 1 May 2020 H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75. According to TipRanks.com, Arce is a 5-star analyst …
Continue reading “Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright”
Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM) Jason Carr AnalystRatings, 1 May 2020 H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00. According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. …
Continue reading “Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)”
Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI) Christine Brown SmarterAnalyst, 1 May 2020 In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17. According to TipRanks.com, Ramakanth is a 1-star analyst with an average …
Continue reading “Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)”
Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA) Christine Brown SmarterAnalyst, 1 May 2020 In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38. According to TipRanks.com, Chen is a 5-star analyst with an average return …
Continue reading “Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)”
Article: Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20 Brandon Evans DBT News, 30 April 2020 Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing …
Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB) Ryan Adist SmarterAnalyst, 30 April 2020 H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62. According to TipRanks.com, Pantginis is a 5-star analyst with an average return of …
Continue reading “Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)”
Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright Austin Angelo SmarterAnalyst, 30 April 2020 In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05. According to TipRanks.com, Fein is a 5-star analyst with an average …
Continue reading “Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright”
Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)
H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV) Austin Angelo SmarterAnalyst, 30 April 2020 In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95. According to TipRanks.com, Pantginis is a 5-star analyst with an average return …
Continue reading “Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)”
Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF) Christine Brown SmarterAnalyst, 29 April 2020 H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23. According to TipRanks.com, Pantginis is a 5-star analyst with an …
Continue reading “Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)”
Article: H.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker
H.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker BusinessWire, 6 February 2020 H.C. Wainwright & Co. announced its #1 Ranking by transaction volume during 2019 maintaining the top position for 19 consecutive quarters in PlacementTracker’s Market League Tables. As noted by PlacementTracker, H.C. Wainwright effectuated more than 3 times the number of transactions …
Continue reading “Article: H.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker”
Article: Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright
Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright TheFly, 10 January 2020 H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020. Read full article. Comment: This appears to be a stellar example …
Article: Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering
Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering GlobeNewswire, 20 December 2019 Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 11,111,116 shares of its common stock and warrants to purchase …
Article: H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)
H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO) Catie Powers Markets.co, 31 October 2019 H.C. Wainwright analyst Swayampakula Ramakanth reiterated a rating on EKSO BIONICS ( – Research Report) today and set a price target of $1.20. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.48. Read full article. …
Continue reading “Article: H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)”
